JNCE

JTX-4014

Metastatic Non-small cell lung cancer (NSCLC)

Phase 2 (Data)

Exp Date

Late 2021

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: JTX-4014 for Metastatic Non-small cell lung cancer (NSCLC)  - Phase 2 Data

  • ClinicalTrials.gov (NCT04549025): Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen (SELECT)


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 2 Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA

PRESS RELEASES


MECHANISM OF ACTION

  • JTX-4014 is a well-characterized fully human IgG4 monoclonal antibody designed to block binding to PD-L1 and PD-L2. Jounce is developing JTX-4014 for potential use in combination with its pipeline of future product candidates. Jounce completed enrollment in the Phase 1 clinical trial of JTX-4014.

Updated by HC

JNCE, Metastatic Non-small cell lung cancer (NSCLC) , JTX-4014

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon